Literature DB >> 29353705

Association between SCN1A gene polymorphisms and drug resistant epilepsy in pediatric patients.

Lucia Margari1, Anna R Legrottaglie2, Alessandra Vincenti3, Giangennaro Coppola4, Francesca F Operto2, Maura Buttiglione2, Amalia Cassano3, Nicola Bartolomeo3, Maria A Mariggiò3.   

Abstract

PURPOSE: "Single Nucleotide Polymorphisms (SNPs)" could be an important explanation of drug resistance in epilepsy. The aim of this study was to investigate if genetic polymorphisms (SNPs) of the SCN1A gene could influence the response to anti - epileptic drugs (AED) and if they could predispose to a drug resistant epilepsy in pediatric patients.
METHODS: We investigated SNPs in exon and intronic regions of the SCN1A gene in a sample of 120 pediatric patients, in both drug-resistant and drug-responsive patients. Association between polymorphisms and refractory epilepsy were investigated by comparing SNPs in exon and intronic regions between the two groups. The genotypes of each intronic polymorphism in the drug-resistant group was analyzed. Odds ratios and confidence intervals were calculated.
RESULTS: None of the SNPs identified in exons of the SCN1A gene were associated with drug-resistance. In the intronic regions, a statistically significant difference was found in the prevalence of three polymorphisms was found between the two patient groups (rs6730344A/C, rs6732655A/T, rs10167228A/T). The analysis of the genotypes of each intronic polymorphism in the drug-resistant group revealed that the AA and AT genotypes for the rs1962842 polymorphism are associated with an increased risk of developing drug resistance compared to TT genotype.
CONCLUSION: The intronic rs6730344, rs6732655 and rs10167228 polymorphisms of the SCN1A gene are a potential risk factors for drug resistance. AA e AT genotype of the rs1962842 intronic polymorphism also emerged as a risk factor in the drug resistant group. Therefore, polymorphisms of the SCN1A gene could play a role in the response to AED in patients with drug-resistant epilepsy, with important implications for clinical practice.
Copyright © 2018 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Drug-resistance; Epilepsy; Intronic polymorphisms; SCN1A

Mesh:

Substances:

Year:  2018        PMID: 29353705     DOI: 10.1016/j.seizure.2018.01.002

Source DB:  PubMed          Journal:  Seizure        ISSN: 1059-1311            Impact factor:   3.184


  5 in total

Review 1.  The Promising Epigenetic Regulators for Refractory Epilepsy: An Adventurous Road Ahead.

Authors:  Vemparthan Suvekbala; Haribaskar Ramachandran; Alaguraj Veluchamy; Mariano A Bruno Mascarenhas; Tharmarajan Ramprasath; M K C Nair; Venkata Naga Srikanth Garikipati; Rohit Gundamaraju; Ramasamy Subbiah
Journal:  Neuromolecular Med       Date:  2022-09-24       Impact factor: 4.103

2.  The possible effect of SCN1A and SCN2A genetic variants on carbamazepine response among Khyber Pakhtunkhwa epileptic patients, Pakistan.

Authors:  Haleema Rehana Nazish; Niaz Ali; Shakir Ullah
Journal:  Ther Clin Risk Manag       Date:  2018-11-21       Impact factor: 2.423

3.  Mapping the knowledge structure and trends of epilepsy genetics over the past decade: A co-word analysis based on medical subject headings terms.

Authors:  Jing Gan; Qianyun Cai; Peter Galer; Dan Ma; Xiaolu Chen; Jichong Huang; Shan Bao; Rong Luo
Journal:  Medicine (Baltimore)       Date:  2019-08       Impact factor: 1.817

4.  Genetic Analysis of Sodium Channel Genes in Pediatric Epilepsy Patients of Pakistan.

Authors:  Aqsa Ashfaq; Tayyaba Saleem; Nadeem Sheikh; Hafsa Maqbool
Journal:  Genet Res (Camb)       Date:  2022-01-29       Impact factor: 1.588

5.  Association of sodium voltage-gated channel genes polymorphisms with epilepsy risk and prognosis in the Saudi population.

Authors:  Mansour A Alghamdi; Laith N Al-Eitan; Ashwag Asiri; Doaa M Rababa'h; Sultan A Alqahtani; Mohammed S Aldarami; Manar A Alsaeedi; Raghad S Almuidh; Abdulbari A Alzahrani; Ahmad H Sakah; Eman Mohamad El Nashar; Mansour Y Otaif; Nawal F Abdel Ghaffar
Journal:  Ann Med       Date:  2022-12       Impact factor: 5.348

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.